Precision medicine in idiopathic pulmonary fibrosis

QJM: An International Journal of Medicine

Volumn 109, Issue 9, 2016, Pages 585-587

  Maher, T M ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); DISEASE COURSE; FIBROSING ALVEOLITIS; HUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; FORECASTING; IDIOPATHIC PULMONARY FIBROSIS; PROCEDURES; TRENDS;

FORECASTING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRECISION MEDICINE;

EID: 84988892448     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcw117     Document Type: Review

References (20)

1. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, Richeldi L, Martinez FJ, et al. Precision medicine: the new frontier in idiopathic pulmonary fibrosis. Am J Respir Critic Care Med 2016; 193:1213-8.
2. Collins FS, Varmus H. A new initiative on precision medicine. New Engl J Med 2015; 372:793-5.
3. Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23:873-6.
4. Schmidt KT, Chau CH, Price DK, Figg WD. Precision oncology medicine: the clinical relevance of patient specific biomarkers used to optimize cancer treatment. J Clin Pharmacol 2016.
5. Hetherington KJ, Heaney LG. Drug therapies in severe asthma - the era of stratified medicine. Clinical Medicine (London, England) 2015; 15:452-6.
6. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-19.
7. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35:496-504.
8. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30:835-9.
9. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45:613-20.
10. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP, MUC5B, and the response to Nacetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Critic Care Med 2015; 192:1475-82.
11. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015; 70:48-56.
12. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L1046-56.
13. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Critic Care Med 2013; 187:768-75.
14. Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1393-402.
15. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000prime Reports 2014; 6:16.
16. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4:549-56.
17. Lyman GH, Moses HL. Biomarker Tests for Molecularly Targeted Therapies-The Key to Unlocking Precision Medicine. New Engl J Med 2016; 375:4-6.
18. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013; 22:148-52.
19. Guenther A, European IPFN. The European IPF Network: towards better care for a dreadful disease. Eur Respir J 2011; 37:747-8.
20. Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015; 3:462-72.